Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 4Stomach Neoplasms 3Gastrointestinal Neoplasms 3Rectal Neuroendocrine Tumors 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Small Size Gastrointestinal Stromal Tumors 1Precancerous Conditions 1Hemorrhage 1Esophageal Neoplasms 1Duodenal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Polyps 1Clinical Stage III Gastric Cancer AJCC v8 1Benign Colon Tumors 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Tranexamic Acid 2carbetocin 1Sutures 1Surgicel 1Solutions 1Sodium Chloride 1Saline Solution 1Neuromuscular Blockade 1N(4)-oleylcytosine arabinoside 1Methylergonovine 1Injections, Intravenous 1FloSeal Matrix 1Ergonovine 1Endoscopic Mucosal Resection 1Bevacizumab 1Aspirin 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemorrhage × Endoscopic Mucosal Resection × 1 year × Clear all
NCT07401303 2026-02-27

Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time

Xijing Hospital of Digestive Diseases

Phase NA Not yet recruiting
640 enrolled
Gastrointestinal

Hemorrhage, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡